Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis.

Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, Lee JH, Yim CY, Kwak JY.

Leuk Lymphoma. 2008 Feb;49(2):247-56. doi: 10.1080/10428190701824536.

PMID:
18231910
2.

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.

Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S.

Haematologica. 2008 Feb;93(2):193-200. doi: 10.3324/haematol.11702. Epub 2008 Jan 26.

3.

Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.

Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, Chen SY.

BMC Cancer. 2008 Jan 13;8:4. doi: 10.1186/1471-2407-8-4.

4.

Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer.

Tang H, Wang J, Bai F, Zhai H, Gao J, Hong L, Xie H, Zhang F, Lan M, Yao W, Liu J, Wu K, Fan D.

Cancer Invest. 2008 Feb;26(1):60-7. doi: 10.1080/07357900701519279.

PMID:
18181047
5.

Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells.

Han S, Wang B, Cotter MJ, Yang LJ, Zucali J, Moreb JS, Chang LJ.

Mol Ther. 2008 Feb;16(2):269-79. Epub 2007 Dec 11.

6.

Biologic predictors in follicular lymphoma: importance of markers of immune response.

Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E.

Leuk Lymphoma. 2007 Dec;48(12):2403-11.

PMID:
18067016
7.

Targeted chronic myeloid leukemia therapy: Seeking a cure.

Fausel C.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. Review.

PMID:
18056932
8.

Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation.

Peng HL, Zhang GS, Liu JH, Gong FJ, Li RJ.

Ann Hematol. 2008 Feb;87(2):121-9. Epub 2007 Nov 13.

PMID:
17999062
9.

New therapies in multiple myeloma.

Merchionne F, Perosa F, Dammacco F.

Clin Exp Med. 2007 Sep;7(3):83-97. Epub 2007 Oct 3. Review.

10.

Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression.

Vogel CF, Li W, Sciullo E, Newman J, Hammock B, Reader JR, Tuscano J, Matsumura F.

Am J Pathol. 2007 Nov;171(5):1538-48. Epub 2007 Sep 6.

11.
12.

FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.

Gjerdrum LM, Woetmann A, Odum N, Burton CM, Rossen K, Skovgaard GL, Ryder LP, Ralfkiaer E.

Leukemia. 2007 Dec;21(12):2512-8. Epub 2007 Aug 23.

PMID:
17713545
13.

Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells.

Ryan EP, Bushnell TP, Friedman AE, Rahman I, Phipps RP.

Cancer Immunol Immunother. 2008 Mar;57(3):347-58. Epub 2007 Aug 1.

PMID:
17668203
14.

Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.

Harris RE.

Subcell Biochem. 2007;42:93-126. Review.

PMID:
17612047
15.
16.

The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis.

M├╝ller-Decker K, F├╝rstenberger G.

Mol Carcinog. 2007 Aug;46(8):705-10. Review.

PMID:
17546626
17.

The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies.

Ribatti D, Vacca A, Rusnati M, Presta M.

Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):327-34. Epub 2007 May 29. Review.

PMID:
17537668
18.

Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma.

Baguma-Nibasheka M, Barclay C, Li AW, Geldenhuys L, Porter GA, Blay J, Casson AG, Murphy PR.

Mol Carcinog. 2007 Dec;46(12):971-80.

PMID:
17477358
19.

Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma.

Irie T, Tsujii M, Tsuji S, Yoshio T, Ishii S, Shinzaki S, Egawa S, Kakiuchi Y, Nishida T, Yasumaru M, Iijima H, Murata H, Takehara T, Kawano S, Hayashi N.

Int J Cancer. 2007 Aug 15;121(4):878-83.

20.

Supplemental Content

Support Center